Sondel Pm
About
In The Last Decade
Sondel Pm
34 papers receiving 2.6k citations
Hit Papers
Peers
Comparison fields: 5 of 79
- Hematology 2.1k
- Immunology 1.6k
- Oncology 736
- Public Health, Environmental and Occupational Health 384
- Genetics 269
Countries citing papers authored by Sondel Pm
This map shows the geographic impact of Sondel Pm's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sondel Pm with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sondel Pm more than expected).
Fields of papers citing papers by Sondel Pm
This network shows the impact of papers produced by Sondel Pm. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sondel Pm. The network helps show where Sondel Pm may publish in the future.
Co-authorship network of co-authors of Sondel Pm
This figure shows the co-authorship network connecting the top 25 collaborators of Sondel Pm. A scholar is included among the top collaborators of Sondel Pm based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sondel Pm. Sondel Pm is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | Children's cancer group trials of interleukin-2 therapy to prevent relapse of acute myelogenous leukemia. | 15 |
| 2 | 1 | |
| 3 | 43 | |
| 4 | 1 | |
| 5 | Graft-versus-leukemia reactions after bone marrow transplantation breakdown → | 2116 |
| 6 | Prospects for interleukin-2 therapy in hematologic malignant neoplasms. | 2 |
| 7 | Limiting dilution analysis of lymphokine-activated killer cell precursor frequencies in peripheral blood lymphocytes of cancer patients receiving interleukin-2 therapy. | 6 |
| 8 | The in vitro function of lymphocytes from 25 cancer patients receiving four to seven consecutive days of recombinant IL-2. | 18 |
| 9 | Transient decrease in IL-2-responsive lymphocytes 24 hours after initiation of continuous IL-2 infusion in cancer patients. | 17 |
| 10 | Clinical testing of IL-2: in vivo administration of IL-2 induces IL-2 dependent non-MHC-restricted cytotoxicity (NRC). | 5 |
| 11 | 44 | |
| 12 | Phase 1 clinical evaluation of recombinant interleukin-2. | 6 |
| 13 | Status and potential of interleukin-2 for the treatment of neoplastic disease. | 8 |
| 14 | Overview: cellular immunotherapy of cancer. | 2 |
| 15 | 4 | |
| 16 | Transplantation of HLA-haploidentical T-cell-depleted marrow for leukemia: autologous marrow recovery with specific immune sensitization to donor antigens. | 16 |
| 17 | Cytotoxicity of autologous Epstein-Barr virus-transformed cells mediated by interleukin-2 dependent, long-term T cell cultures is augmented by beta, but not alpha, recombinant interferon. | 2 |
| 18 | Clinical trial depleting T lymphocytes from donor marrow for matched and mismatched allogeneic bone marrow transplants. | 44 |
| 19 | Antitumor cytotoxic T cells and non-T-cells generated by allosensitization in vitro. | 6 |
| 20 | 22 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.